Harm and Medication-Type Impact Agreement with Hypothetical Deprescribing Recommendations: a Vignette-Based Experiment with Older Adults Across Four Countries
Open Access
- 14 November 2022
- journal article
- research article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (6) , 1439-1448
Abstract
Background Little is known about what factors are important to older adults when deciding whether to agree with a recommendation to deprescribe. Objective To explore the extent to which medication type and rationale for potential discontinuation influence older adults’ acceptance of deprescribing. Design Cross-sectional 2 (drug: lansoprazole — treat indigestion; simvastatin — prevent cardiovascular disease) by 3 (deprescribing rationale: lack of benefit; potential for harm; both) experimental design. Participants Online panelists aged ≥65 years from Australia, the Netherlands, the United Kingdom, and the United States Interventions Participants were presented with a hypothetical patient experiencing polypharmacy whose PCP discussed stopping a medication. We randomized participants to receive one of six vignettes. Main Measures We measured agreement with deprescribing (6-point Likert scale, “Strongly disagree (1)” and “Strongly agree (6)”) for the hypothetical patient as the primary outcome. We also measured participants’ personality traits, perceptions of risk and uncertainty, and attitudes towards polypharmacy and deprescribing. Key Results Among 5311 participants (93.3% completion rate), the mean (M) agreement with deprescribing for the hypothetical patient was 4.71 (95% confidence interval (CI): 4.67, 4.75). Participants reported higher agreement with stopping lansoprazole (n=2656) (M=4.90, 95% CI: 4.85, 4.95) compared to simvastatin (n=2655) (M=4.53, 95% CI: 4.47, 4.58), P<.001. Participants who received the combination rationale (n=1786) reported higher agreement with deprescribing (M=4.83, 95% CI: 4.76, 4.89) compared to those who received the rationales on lack of benefit (n=1755) (M=4.66, 95% CI: 4.60, 4.73) or potential for harm (n=1770) (M=4.65, 95% CI 4.58, 4.72). In adjusted regression analyses (n=5062), participants with a higher desire to engage in health promotion behaviors (b=0.08, 95% CI 0.02, 0.13) or need for certainty (b=0.12, 95% CI 0.04, 0.20) reported higher agreement with deprescribing. Conclusions Older adults across four countries were accepting of deprescribing in the setting of polypharmacy. The medication type and rationale for discontinuation were important factors in the decision-making process. Trial Registration ClinicalTrials.gov, NCT04676282, https://clinicaltrials.gov/ct2/show/NCT04676282?term=vordenberg&draw=2&rank=1Keywords
This publication has 48 references indexed in Scilit:
- Clinical consequences of polypharmacy in elderlyExpert Opinion on Drug Safety, 2013
- Patient Barriers to and Enablers of Deprescribing: a Systematic ReviewDrugs & Aging, 2013
- Development and validation of the patients’ attitudes towards deprescribing (PATD) questionnaireInternational Journal of Clinical Pharmacy, 2012
- “It’s just routine.” A qualitative study of medicine-taking amongst older people in New ZealandPharmacy World & Science, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesAnnals of Internal Medicine, 2007
- Brief Report: screening items to identify patients with limited health literacy skillsJournal of General Internal Medicine, 2006
- Attitudes and uptake of a screening test: The moderating role of ambivalencePsychology & Health, 2006
- Mortality prediction with a single general self-rated health questionJournal of General Internal Medicine, 2006
- Intention to Participate in Predictive Genetic Testing for Hereditary Cancer: The Role of Attitude toward UncertaintyPsychology & Health, 2002
- The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medicationPsychology & Health, 1999